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Abstract  
The prevalence of vitamin D insufficiency and deficiency has increased markedly in recent 
decades to current epidemic levels1. In parallel there has been an increase in the incidence of 
a range of immune-mediated conditions ranging from cancer to autoimmune and respiratory 
diseases, including chronic obstructive pulmonary disease and asthma2,3. There is also an 
association with increased respiratory infections, which are the most common cause of asthma 
exacerbations3. Together, this has resulted in considerable interest in the therapeutic potential 
of vitamin D to prevent and improve treatment of asthma and other respiratory diseases. To 
this end, data from clinical trials involving supplementation with active vitamin D, or more 
commonly a precursor, are starting to emerge. This review considers mechanisms by which 
vitamin D may act on the immune system to dampen inappropriate inflammatory responses in 
the airway whilst also promoting tolerance and anti-microbial defence mechanisms that 
collectively maintain respiratory health. 
 
Asthma 
Heterogeneity in asthma phenotypes (referred to as endotypes) has been described and these 
endotypes demonstrate differential responsiveness to treatment, underpinned by distinct 
pathogenic mechanisms4-7. Asthma is classically a steroid-sensitive Th2-type immune 
pathology8 and the symptoms of asthma are well-controlled by β2-adrenergic agonists and 
inhaled corticosteroids in the majority of patients.  However, these long-term treatments do 
not ‘cure’ the disease, and the daily regimen of inhalers and avoidance of asthma triggers has 
a significant negative impact on many patients’ quality of life.  Furthermore, there are 
endotypes of asthma in which corticosteroid treatment is clinically ineffective (steroid 
insensitive/refractory/resistant asthma)9. These steroid-refractory patients suffer considerable 
morbidity, and are both expensive and challenging to manage clinically. 
 
Vitamin D biology 
Vitamin D is primarily synthesised by ultraviolet-B radiation from sunlight photolysing skin 
resident 7-dehydrocholesterol into vitamin D3, but it is also be ingested in small amounts 
through the diet (e.g. in oily fish or dietary supplements). Vitamin D then undergoes step-wise 
metabolism, first by the enzyme CYP27A1 in the liver into 25-hydroxyvitamin D3 (25(OH)D), 
the major form of vitamin D in the body, and then by the mitochondrial enzyme CYP27B1 to 
the active metabolite (1α,25-dihydroxyvitamin D3 (1,25(OH)2D3))10.  Circulating 1,25(OH)2D3 
is principally formed by CYP27B1 in the kidney and acts to regulate calcium-phosphate 
homeostasis. However, high levels of local tissue 1,25(OH)2D3 can be produced by CYP27B1, 
which is also expressed by a diverse range of parenchymal and immunological cell types, 
including epithelial cells, macrophages and dendritic cells. In vitro studies show these cell 
types are able to produce 1x10-9M to 6x10-8M 1,25(OH)2D3 from 25(OH)D in culture11-14. The 
active form of vitamin D, 1,25(OH)2D3, principally regulates cellular responses by altering 
gene transcription - it binds to the vitamin D receptor (VDR), altering the binding of the VDR 
to genomic vitamin D response elements (VDREs) leading to changes in transcription of VDRE 
regulated genes. The VDR is expressed by essentially all cells of the immune system and 
parenchymal cells, particularly upon activation, which enables them to respond to 
1,25(OH)2D310. Furthermore, VDREs are present throughout the genome, including in the 
promoter regions for many genes associated with autoimmune diseases15. The actions of 
1,25(OH)2D3 are however limited due to rapid catabolism by CYP24A1, an enzyme that is 
also expressed by structural and immune cells16.  
Measurement of circulating 25(OH)D, as the major form of vitamin D in the body, is used to 
assess an individual’s vitamin D status. There is an ongoing debate as to what comprises 
sufficiency, although in general terms serum 25(OH)D of less than 20ng/ml (50nmol/l) defines 
deficiency and 20-30ng/ml (50-75nmol/l) indicates insufficiency17. Factors including genetic 
diversity, skin colour, obesity, season and lifestyle all influence vitamin D status, but in most 
populations studied, insufficiency is a problem17.  
 
Vitamin D and Asthma – Epidemiological Evidence 
A large study by Black et al. in 200518 was one of the first to highlight the positive association 
between vitamin D status and pulmonary health. Multiple studies have confirmed this finding, 
and in particular show that, compared to non-asthmatic controls, the incidence of vitamin D 
insufficiency is greater amongst paediatric patients19-21 and adults22 with asthma. Serum 
25(OH)D demonstrates a negative correlation with the severity of asthma (e.g. number of 
exacerbations)20,23 and the requirement for higher dose corticosteroids22,24,25, an effect which 
is seen most strongly in paediatric cohorts (reviewed in Gupta et al., 201226). Inverse 
correlations have also been documented between serum 25(OH)D and airway remodeling, 
IgE, eosinophil numbers as well as airway hyper responsiveness20,22,25 (recently reviewed in 
Mann et al., 201427). Furthermore, a remarkable number of asthma-associated genes are 
known to be vitamin D regulated and polymorphisms within the VDR have been associated 
with an increased risk of asthma28-31. 
There are many mechanisms through which vitamin D status may influence asthma and 
pulmonary health, and which would explain the above epidemiological and genetic 
associations. The discussion in the following sections reveals the diversity of pathways 
influenced by vitamin D. However asthma itself may influence vitamin D status (reverse-
causation). Conceptually asthmatics, especially those with pollen sensitivity, may spend a 
reduced amount of time outside exposed to sunlight, however, limited available evidence does 
not suggest that this is a significant explanation32. Inflammation itself is now known to affect 
vitamin D metabolism and a large inflammatory response can cause deterioration in vitamin 
D status33. One of the severe asthma phenotypes is characterised by obesity34, which can 
itself cause decreased circulating vitamin D levels possibly due to sequestration of vitamin D 
in fat35,36. Furthermore corticosteroids, the corner-stone of asthma treatment, affect vitamin D 
metabolism and in particular increase VDR and CYP24A1 expression37-39. 
It is most likely that the association between asthma and vitamin D insufficiency is multi-
factorial, and underpinned by both mechanisms of causation and reverse-causation. The 
current epidemic of vitamin D insufficiency may predispose the immune system to excessive 
immunological responses such as seen in asthma, which may in turn cause further worsening 
of vitamin D status (and in turn further worsening of asthma). Issues of reverse-causation do 
not mechanistically exclude vitamin D therapies as treatments for asthma in relevant patient 
groups. 
 
Mechanisms by which vitamin D maintains respiratory health and regulates pulmonary 
immune responses 
Effects on innate immunity relevant to asthma 
Respiratory tract infections (RTIs) are a major cause of asthma exacerbations40, and chronic 
infection may contribute to the development of severe asthma41. Cross sectional, case-control 
and cohort studies have repeatedly shown an inverse correlation between serum 25(OH)D 
and the incidence of acute RTIs42,43. There are multiple mechanisms by which vitamin D may 
enhance anti-microbial responses and beneficially modulate the inflammatory response to 
bacteria, viruses and fungi44 (Figure 1). 
Pathogen challenge by antigen presenting cells triggers toll-like receptors (TLRs), and TLR 
stimulation has been shown to enhance CYP27B1 expression in a variety of cell types 
resulting in increased expression of vitamin D-dependent pathways14,45. Many allergens can 
also stimulate cells through TLRs. In particular, a prominent response to the combination of 
TLR stimulation and vitamin D in monocytes, macrophages and epithelial cells is the induction 
of anti-microbial peptides such as cathelcidin and -defensin-2. These molecules contribute 
to host defence through direct anti-microbial activity, as well as by modulating innate and 
adaptive immunity in addition to wound repair. Although the focus of studies regarding anti-
microbial peptide actions has been in bacterial infections, they also appear to be important for 
anti-viral and anti-fungal immunity46,47. The enhancement of anti-microbial peptide expression 
by vitamin D is accompanied by modulation of the production of pro-inflammatory cytokines 
which is hypothesised to lead to enhanced pathogen clearance without an excessive 
inflammatory response48. Furthermore, vitamin D stimulates autophagy and autophagosome 
activity which are important in the anti-microbial response49. 
 
Effects on the adaptive immune system 
The primary, but complex, role of vitamin D in dendritic cell (DC) function is modulation of 
antigen presenting cell function50,51. For example, vitamin D decreases MHC and costimulatory 
molecule expression by myeloid DCs52.  Since the magnitude and nature of T cell responses 
is directly influenced by antigen presenting cells, vitamin D-mediated modulation of DC 
functions has a major effect on downstream lymphocyte responses. Furthermore, vitamin D 
has direct effects on T cells, impacting on T cell expansion, phenotype, and cytokine profiles.  
Vitamin D consistently inhibits Th1-associated cytokine synthesis in culture and in animal 
models53. However, the effects on Th2 responses relevant to allergic and asthmatic disease 
are more complex although particularly important because Th2 cytokines play a central role 
in driving IgE synthesis. Vitamin D has been reported to both inhibit or promote Th2 responses 
in different animal models and human T cell culture systems54, a significant concern in early 
studies investigating the potential of vitamin D to improve asthma control. We have reported 
a non-linear dose effect of 1,25(OH)2D3 in culture on Th2 and Th1 responses55 (Figure 2), the 
relevance of which has become more apparent following epidemiological observations relating 
IgE levels to serum vitamin D status. Studies by Wjst and colleagues suggested that high 
levels of vitamin D in early life were associated with an increase in allergic disease at 30-
years56. Subsequently, Hypponen, an author on those earlier studies, demonstrated in a very 
large cohort that circulating 25(OH)D levels exhibited a non-linear relationship with serum IgE; 
elevated IgE was only observed at very low or high 25(OH)D levels57. We and others, have 
since reported that serum 25(OH)D levels negatively correlate with total and aeroallergen-
specific IgE20,58. In vitro, 1,25(OH)2D3 reduces the production of IgE from peripheral human B 
cells and increases B cell synthesis of the immunoregulatory cytokine IL-1059,60. Notably IL-10 
producing B cells synthesise IgG4, an isotype associated with beneficial outcome following 
allergen desensitization immunotherapy61. Together these data suggest both a non-linear 
relationship of vitamin D status with immune parameters associated with allergic and 
asthmatic disease (see model Figure 1), and the existence of compensatory mechanisms to 
counter vitamin D enhancement of Th2 responses.  
IL-17A, and other Th17-associated cytokines, play a central role in defence against bacterial 
and fungal mucosal infections. However excessive levels of these cytokines, particularly IL-
17A, is implicated in severe asthma and other immune-mediated diseases. Many patients with 
severe asthma have a neutrophilic endotype that is associated with increased IL-17A 
levels/production62-67. In addition to triggering neutrophilia, IL-17A promotes airway hyper-
responsiveness and remodelling, steroid-resistance, and synthesis of pro-inflammatory 
cytokines66-69. Vitamin D has been shown to reduce IL-17A responses, both in mice and in 
humans with severe asthma65,70.  
 
Effects on regulatory T lymphocyte responses 
Regulatory T cells (Tregs) are essential to prevent and control inappropriate and excessive, 
immune responses including those associated with allergy and asthma (reviewed in71). 
However, the frequency and action of Tregs in addition to levels of anti-inflammatory IL-10 are 
diminished in asthma patients72,73. For example, bronchial lavage from severe therapy-
resistant paediatric asthmatics contains lower levels of IL-10 compared to non-asthmatic 
subjects, whilst the production of IL-10 by PBMCs/T cells from both paediatric and adult severe 
asthma patients is reduced74,75. 
Vitamin D enhances multiple facets of Treg actions76 – including promoting distinct 
CD4+Foxp3+ and CD4+IL-10+ (Tr1/IL-10-Treg) populations in vitro and upregulating 
expression of the inhibitory costimulatory molecules CTLA-4 and PD177-80. Interestingly, the 
nature of the regulatory T cells enhanced by vitamin D is strongly dependent on the 
concentration of vitamin D and local cytokine milieu; for example varying vitamin D 
concentrations in different cytokine environments enhance IL-10 expressing Tregs and 
FoxP3+ Tregs in a mutually exclusive manner79,81. In support of these observations, a positive 
correlation exists between serum 25(OH)D and expression of Foxp3 on peripheral CD4+ T 
cells, numbers of circulating Foxp3+ T cells as well as levels of IL-10 in the BAL24,74,82,83.  
In addition to enhancing distinct Treg subsets, vitamin D also affects many other immune 
regulatory pathways, for example lymphocyte ATP metabolism and CD200 expression. 
CD200 suppresses the pro-inflammatory activity of local innate immune cells and 
1,25(OH)2D3 has been shown to increase expression of CD200 on human peripheral and 
nasal airway human T cells84. ATP is a proinflammatory molecule that can be broken down 
into immunosuppressive adenosine via the action of 5’-ectonucleotidases CD39 (ATP/ADP 
into AMP) and CD73 (AMP into adenosine)85. Both CD39 and CD73 have been proposed as 
Treg markers and CD39 expression at least is downregulated in severe asthmatics65,86. We 
have shown that in vitro, 1,25(OH)2D3 upregulates CD39 expression and that this contributes 
to suppression of IL-17A65. 
 
Effects on corticosteroid responses 
Early studies from our laboratory investigated immunological actions of glucocorticoids that 
were relevant to clinical efficacy. We demonstrated that peripheral blood CD4+ T cells from 
steroid refractory patients were unable to increase secretion of anti-inflammatory IL-10 in vitro 
when treated with dexamethasone (a synthetic corticosteroid), unlike cells from steroid 
sensitive individuals and healthy controls75. However, vitamin D, either by addition of 
1,25(OH)2D3 to cultures or by oral supplementation of the steroid refractory asthmatics 
themselves for 7 days, restored the dexamethasone induction of IL-1075. In addition to directly 
enhancing IL-10 production, we reported that 1,25(OH)2D3 can overcome downregulation of 
the glucocorticoid receptor by dexamethasone. This work led directly to a small proof of 
concept placebo-controlled clinical study demonstrating clinical steroid-enhancing effects of 
calcitriol in steroid refractory asthma87. A steroid-enhancing role for vitamin D in severe asthma 
is strongly supported by observational studies, particularly in paediatric cohorts25,26. In addition 
to our T cell studies, Zhang et al.88 have pioneered studies of the anti-inflammatory and 
corticosteroid-enhancing actions of vitamin D in monocytes in both steroid refractory and 
sensitive asthma patients. 
We recently reported that dexamethasone upregulates IL-17A from PBMC and CD4+ T cells 
in vitro, and demonstrated a positive association between inhaled corticosteroid dose 
(beclomethasone equivalent) and IL-17A synthesis in culture. These data suggest that 
corticosteroids may contribute to progression in severe asthma by heightening the Th17 
responses. Notably, vitamin D strongly inhibited the corticosteroid induced IL-17A in culture65. 
 
Effects of vitamin D on airway remodelling 
Airway remodelling in asthma irreversibly reduces lung function, and in general is poorly-
controlled with current therapies89. Vitamin D has been shown to reduce airway smooth 
muscle (ASM) mass, subepithelial deposition and goblet cell hyperplasia90,91 (Figure 1). 
Similarly, an inverse correlation exists between ASM mass and serum 25(OH)D in paediatric 
asthmatics20, whilst addition of vitamin D derivatives to cultures of human ASMs impairs 
proliferation of cells92. Furthermore, vitamin D has been shown to reduce production of 
extracellular matrix proteins from fibroblasts and reduce expression of enzymes implicated in 
airway remodelling, namely ADAM33 and MMP993-96. 
 
Vitamin D and Fetal Development 
The majority of asthmatic patients develop the disease within the first decade of life, often 
following on from the development of food allergies and hayfever in the first years of life – the 
atopic march97. This strongly suggests that events in the fetal environment and first months of 
life have a major effect on whether individuals develop asthma. Lower maternal intake of 
vitamin D and maternal vitamin D deficiency have been found to be associated with increased 
risk of wheeze/asthma during childhood, both in individual studies and a meta-analysis98-102. 
However some studies show no affect102-105 others even an adverse affect106,107; disparity in 
outcomes from clinical studies could be due to a variety of factors summarized in Figure 3. 
Importantly, maternal vitamin D intake is not equivalent to maternal or fetal vitamin D status 
as diet is only a minor source of vitamin D and different vitamin D supplements contain very 
different amounts of vitamin D. Furthermore assessment of the response to vitamin D 
supplements is complicated by supplements often containing other constituents such as 
vitamin A that have their own actions on the developing immune system108-110. The importance 
of maternal vitamin D status is underpinned by the fact that the placenta is a major site for the 
conversion of 25(OH)D3 to 1,25(OH)2D3111,112. In addition to its actions on the developing 
immune system, vitamin D has an important role in fetal lung development113,114.  
 
Clinical Trials of Vitamin D Therapies – Early Evidence 
Given current disagreements as to the definition of vitamin D sufficiency and deficiency, it is 
not surprising that there is also debate on how to design trials of vitamin D therapies.  Different 
molecular forms of vitamin D may be more or less effective as therapeutic supplements, as 
well as different dosing regimens. Whether all individuals would benefit from vitamin D 
supplements or only those with levels below certain thresholds, or only those with certain 
diseases (and certain endotypes of those diseases) is uncertain. Few studies so far published 
have investigated vitamin D therapies in asthma and given the uncertainties above, it is not 
surprising these trials have not reached unanimous conclusions.  
In one randomized, double-blind placebo-controlled (RCT) trial 48 children (5-18 years) with 
newly diagnosed asthma received either budesonide with placebo or budesonide with 500IU 
vitamin D daily, a comparatively low dose115. The authors observed that vitamin D 
supplementation in the period from September to July prevented declining serum 
concentrations of 25(OH)D and reduced the risk of asthma exacerbation triggered by acute 
respiratory tract infection. In addition to such studies in children, we recently reported in a RCT 
that 1,25(OH)2D3 led to a modest improvement in the clinical response to oral steroids in a 
small cohort of adult steroid resistant asthma patients87.  
The large VIDA trial of vitamin D supplementation in vitamin D insufficient asthmatics recently 
reported its outcomes105 The primary outcome, time to first asthma treatment failure, was not 
significantly affected by vitamin D supplementation. There was however a trend towards a 
reduced overall rate of exacerbations in the vitamin D treated group (P=0.05) and significantly 
greater reduction in inhaled corticosteroid dose. Possible reasons that the primary outcome 
measure did not show a significant benefit of vitamin D supplementation include the study 
being underpowered, some vitamin D treated participants not attaining vitamin D sufficiency 
and that vitamin D may only be beneficial in particular asthma endotypes. 
Data from other large trials in asthma are awaited.  
 
Conclusions and viewpoint 
Evidence from clinical initiatives is starting to emerge, in both asthma and respiratory 
infections. However the data are likely to be complex and reflect the heterogeneity in trial 
design. It seems probable based on findings to date, and when placed in the context of 
experimental data, that beneficial effects are most likely to be observed in individuals who are 
profoundly vitamin D deficient. It should however be considered that the body has numerous 
measures to compensate for low levels of vitamin D intake via mechanisms including 
parathyroid hormone. Consequently, there may well be a non-linear relationship between 
intake of vitamin D and its biological effects, an observation that is supported by certain 
immunological findings.  
In summary there are many pathways pertinent to asthma that are strongly influenced by 
vitamin D. We strongly believe that future trials of vitamin D therapies in asthma need to 
consider the above issues. In our opinion smaller trials of vitamin D in specific asthma 
endotypes with asthma-relevant endpoints suggested by clinical science is the way forward. 
 
Figure legend 
Figure 1. The immunomodulatory properties of vitamin D relevant to asthma  
Vitamin D modulates immune activity in a multitude of ways. Generally a more regulatory 
environment is promoted by upregulation of Treg numbers and activity, as well as reduced 
pro-inflammatory cytokine production. Clinically the incidence of infections is reduced, airway 
remodelling halted and corticosteroid responsiveness improved.   
 
Figure 2. Non-linear association of vitamin D levels with immune parameters of 
relevance to allergic and asthmatic disease. 
This cartoon illustrates the non-linear (U-shaped) association of serum 25-hydroxyvitamin D3 
levels with IgE; and a non-linear dose effect of 1alpha,25-dihydroxyvitamin D3 in culture on 
the inhibition of Th2 and enhancement of IL-10 responses55,57. 
 
Figure 3. Factors that differ between vitamin D clinical studies and may account for 
observed differences in results.   
Differences in the participant cohort and study design are evident in vitamin D clinical studies 
and are likely to contribute to variation in the results. Summarised here are the key factors that 
need to be taken into consideration.   
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